Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SOM230 s.c · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SOM230 s.c. | DRUG | - |
Inclusion Criteria: * Patients with pituitary Cushing's disease within the two months prior to study entry * Patients for whom written informed consent to participate in the study has been obtained * Female patients of child bearing potential who have not undergone clinically documented total hyste...
SOM230 s.c is an investigational small molecule being studied for the treatment of Cushing's Syndrome, a condition caused by excess cortisol. It is administered subcutaneously and is currently in clinical development, having completed a Phase 2 trial.
SOM230 s.c is a somatostatin analog that targets somatostatin receptors. By binding to these receptors, it is designed to inhibit the secretion of adrenocorticotropic hormone (ACTH), which can help reduce cortisol levels in patients with Cushing's Syndrome.
SOM230 s.c is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol NVS. The drug is in Phase 2 clinical development for the treatment of Cushing's Syndrome.
SOM230 s.c is in Phase 2 clinical development. It has completed one Phase 2 trial, which was an uncontrolled study involving 26 patients with Cushing's Syndrome. The drug is not yet approved and remains investigational.
SOM230 s.c has been studied in one clinical trial with the identifier NCT00088608. This Phase 2 trial, titled 'A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease,' was completed in the United States and enrolled 26 adult patients with Cushing's Syndrome.
SOM230 s.c is also known as pasireotide, a somatostatin analog. It is being developed by Novartis AG for the treatment of Cushing's Syndrome and has completed a Phase 2 clinical trial under the identifier NCT00088608.